Ainos (AIMD) Competitors $3.29 +0.10 (+3.13%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. XCUR, VOR, ARTV, KLTO, ATHE, ITRM, KPTI, AKTX, ACRV, and CLNNShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Exicure (XCUR), Vor Biopharma (VOR), Artiva Biotherapeutics (ARTV), Klotho Neurosciences (KLTO), Alterity Therapeutics (ATHE), Iterum Therapeutics (ITRM), Karyopharm Therapeutics (KPTI), Akari Therapeutics (AKTX), Acrivon Therapeutics (ACRV), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Its Competitors Exicure Vor Biopharma Artiva Biotherapeutics Klotho Neurosciences Alterity Therapeutics Iterum Therapeutics Karyopharm Therapeutics Akari Therapeutics Acrivon Therapeutics Clene Exicure (NASDAQ:XCUR) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Is XCUR or AIMD more profitable? Ainos' return on equity of -88.07% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -353.47% -96.50% Ainos N/A -88.07%-48.60% Which has higher valuation & earnings, XCUR or AIMD? Exicure has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K81.28-$9.70M-$3.82-1.68Ainos$20K689.26-$14.86M-$1.29-2.55 Do insiders and institutionals hold more shares of XCUR or AIMD? 42.8% of Exicure shares are held by institutional investors. 3.9% of Exicure shares are held by insiders. Comparatively, 10.4% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to XCUR or AIMD? In the previous week, Exicure had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Exicure and 1 mentions for Ainos. Exicure's average media sentiment score of 0.20 beat Ainos' score of -0.50 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ainos 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has more volatility and risk, XCUR or AIMD? Exicure has a beta of 3.57, suggesting that its stock price is 257% more volatile than the S&P 500. Comparatively, Ainos has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. SummaryExicure and Ainos tied by winning 6 of the 12 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.79M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-0.519.1027.5120.24Price / Sales689.26682.84416.89118.64Price / CashN/A158.5936.8958.07Price / Book0.604.588.035.67Net Income-$14.86M$31.34M$3.18B$249.13M7 Day Performance31.60%3.25%2.90%3.28%1 Month Performance1.59%7.08%3.71%5.56%1 Year Performance-20.18%0.17%36.03%21.13% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.8251 of 5 stars$3.29+3.1%N/A-30.0%$13.79M$20K-0.5140XCURExicure1.9871 of 5 stars$5.72-12.0%N/A+1,940.0%$41.07M$500K-1.1950Earnings ReportVORVor Biopharma3.9939 of 5 stars$0.32+9.7%$7.06+2,118.5%+104.9%$39.75MN/A-0.19140Analyst RevisionGap UpHigh Trading VolumeARTVArtiva Biotherapeutics2.2525 of 5 stars$1.61-0.6%$17.80+1,005.6%N/A$39.47M$250K0.0081KLTOKlotho NeurosciencesN/A$1.44+20.0%N/AN/A$38.99MN/A-4.00N/AAnalyst UpgradeATHEAlterity Therapeutics2.6502 of 5 stars$4.43+1.3%$12.00+171.2%+122.3%$38.75MN/A0.0010ITRMIterum Therapeutics1.9197 of 5 stars$0.98+4.1%$9.00+814.9%-15.1%$37.78MN/A-0.9910News CoverageKPTIKaryopharm Therapeutics3.8596 of 5 stars$4.65+7.4%$43.20+829.0%-62.8%$37.41M$145.24M-0.35380AKTXAkari Therapeutics1.5503 of 5 stars$1.16flatN/A-62.9%$37.33MN/A0.009ACRVAcrivon Therapeutics2.6395 of 5 stars$1.24+5.1%$17.71+1,328.6%-78.9%$37MN/A-0.5658CLNNClene2.3011 of 5 stars$4.12+0.5%$40.00+870.9%-39.9%$36.83M$340K-1.02100News CoverageGap Up Related Companies and Tools Related Companies XCUR Competitors VOR Competitors ARTV Competitors KLTO Competitors ATHE Competitors ITRM Competitors KPTI Competitors AKTX Competitors ACRV Competitors CLNN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIMD Stock Alerts